№ lp_2_3_49629
File format: docx
Character count: 9686
File size: 53 KB
Year:
2023
Region / city:
Not specified
Topic:
Ophthalmology, Medical Drugs
Document Type:
Medical Authorization Form
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Healthcare Providers
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Context:
Medical request form for prior authorization of ophthalmic VEGF inhibitors, detailing drug choices and criteria for approval.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Egypt, Benha
Subject:
Hepatitis C, Hepatocellular carcinoma, Biomarkers
Document Type:
Research Article
Institution:
Benha University, Faculty of Medicine
Departments:
Medical Microbiology and Immunology; Hepatology, Gastroenterology and Infectious Diseases
Authors:
Amal M. Matta, Reem R. Abd El-Galil, Hala A. Tabl, Heba-Allah F. El-Marakby, Ahmed S. Elgazar
Ethical Approval:
Benha University Academic and Ethical Committee
Participants:
90 (32 CHC, 23 CHC with liver cirrhosis, 20 CHC with HCC, 15 healthy controls)
Methods:
Real-time PCR for miR-34a, ELISA for VEGF
Data Collection Period:
Not specified
Key Findings:
miR-34a downregulated in HCV patients with HCC and cirrhosis; VEGF levels elevated in disease progression
Year:
2023
Region / City:
Indianapolis, IN
Topic:
Periodontal Regeneration
Document Type:
Research Article
Institution:
Indiana University School of Dentistry
Authors:
Raziel Velgis, L. Jack Windsor, Vanchit John, Chandni Batra
Target Audience:
Researchers, Dental Professionals
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Keywords:
rhPDGF-BB, VEGF, Periodontal Ligament Cells, Proliferation, Regeneration
Context:
A research article investigating the effects of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) on the proliferation of periodontal ligament cells and VEGF expression.
Document type:
Medical necessity letter
Therapeutic area:
Ophthalmology
Indication:
Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Medication name:
VYZULTA (latanoprostene bunod ophthalmic solution)
Dosage strength:
0.024%
Drug class:
Prostaglandin analogue with nitric oxide–donating activity
Regulatory status:
FDA-approved prescription medication
Manufacturer:
Bausch & Lomb Inc.
Intended recipient:
Health insurance payer or medical director
Target population:
Patients with open-angle glaucoma or ocular hypertension
Clinical evidence referenced:
Phase 2 VOYAGER study; Phase 3 APOLLO and LUNAR studies; real-world retrospective studies
Safety information included:
Yes
References:
Peer-reviewed journals and prescribing information
Source type:
Industry-provided informational material
Year:
2019
Region / city:
Australia
Subject:
Medical Device Registration
Document Type:
Medical Application
Organization:
Seqirus (Australia) Pty Ltd
Author:
Seqirus
Target Audience:
Medical practitioners, optometrists, and healthcare professionals
Period of validity:
Not specified
Approval Date:
July 2019
Modification Date:
Not specified
Effective date:
1 August 2006
Document type:
Administrative mandate
Sector:
General Ophthalmic Services
Regulatory framework:
GOS Terms of Service
Subject:
Authorised signatories for GOS1 forms
Jurisdiction:
United Kingdom
Signatory requirements:
Practitioner and Contractor signatures under specified circumstances
Scope:
Financial and regulatory responsibilities for GOS claims
Supersedes:
All previous practice mandates
Change procedure:
New mandate required for any change in signatories
Type of document:
Research study abstract and introduction
Field:
Pharmaceutics
Topic:
Ocular drug delivery
Drug studied:
Erythromycin
Drug class:
Macrolide antibiotic
Dosage form:
Microemulsion
Oil phase:
Oleic acid
Surfactant:
Tween 80
Co-surfactant:
Ethanol
Aqueous phase:
0.5 N NaOH
Experimental design:
2³ factorial design
Evaluated parameters:
Particle size, viscosity, pH, drug content
Particle size range:
12.11–650.6 nm
Drug content range:
79.55%–95.56%
Optimized formulation:
F1
Keywords:
Microemulsion, Ocular delivery, Surfactant, Amphiphile, Conjunctivitis, Evaluation
Document type:
Application form
Subject:
Provision of General Ophthalmic Services
Contract type:
GOS contract (individual, partnership or body corporate)
Governing legislation:
Partnership Act 1890
Note:
Governing legislation
Limited Partnership Act 1907
Regulatory framework:
General Ophthalmic Service Contracts Regulations 2008
Regulatory body:
NHS England
Geographical scope:
East Midlands and West Midlands
Relevant register:
NHS England Performers List
Professional regulator:
General Optical Council (GOC)
Required documentation:
Professional indemnity insurance and public liability insurance evidence
Sections:
Section A – Mandatory services; Section B – Declaration
Applicants:
Individual practitioners, partnerships, limited partnerships, limited liability partnerships, body corporates
Information required:
Practice details, partners, professional staff, equipment, record-keeping arrangements, confidentiality responsibility, contract start date
Submission method:
Email to designated NHS England regional addresses
Year:
2026
Region / City:
Not specified
Subject:
Veterinary ophthalmic procedures
Document Type:
Practicum evaluation rubric
Institution:
Veterinary training program
Author:
Not specified
Target Audience:
Veterinary students
Evaluation Points:
50
Skills Assessed:
Medication administration, handling of animal eyes, hygiene, professionalism
Procedure:
Steps for applying ophthalmic drops or ointment to animals
Assessment Date:
Not specified
Year:
2025
Region / City:
Global
Subject:
Ophthalmic Photography
Document Type:
Correction Proposal
Organization:
DICOM Standards Committee
Authors:
Nayoon Gim, Aaron Lee, Harry Solomon
Target Audience:
Medical Imaging Professionals
Effective Period:
2024-2025
Approval Date:
2024/05/06
Date of Last Update:
2025/01/27
Correction Number:
CP-2416
Correction Summary:
Update PS3.3 and PS3.16 standards to include support for Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO)
End of Validity Period:
N/A
Keywords:
Ophthalmic Photography, FLIO, DICOM, Medical Imaging, Standards Update
Year:
2024
Region / City:
Not specified
Subject:
Ophthalmology, Uveitis Treatment
Document Type:
Training Assessment
Institution:
Not specified
Author:
Not specified
Target Audience:
Medical trainees in ophthalmology
Validity Period:
Not specified
Approval Date:
Not specified
Date of Modifications:
Not specified
Year:
2026
Region / City:
Midland
Topic:
Job Description
Document Type:
Job Posting
Organization:
Midland Eye
Author:
Midland Eye HR Department
Target Audience:
Potential Job Candidates
Period of Validity:
Ongoing
Approval Date:
2026
Date of Changes:
N/A
Book Name:
Medical Science: Recent Advances and Applications
Manuscript Number:
Ms_BPR_5206
Type of the Article:
Book Chapter
Source Article:
Journal of Ocular Sciences and Ophthalmology, 2024, 5(2): 180047
Journal:
Journal of Ocular Sciences and Ophthalmology
Reviewer:
Ragni Kumari
Institution:
Era University, India
Field:
Ophthalmology
Subject:
High-index ophthalmic lenses, chromatic aberration, visual performance, high myopia
Document Type:
Peer Review Form
Publication Status:
Extended version of previously published journal article
Peer Review Policy Note:
Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review
Language:
English
Continued Professional Development (CPD) Allowance Claim Form 2023 for NHS Ophthalmic Services Wales
Year:
2023
Region / city:
Wales
Target group:
Optometrists, Ophthalmic Medical Practitioners, Independent Prescribing Optometrists, Dispensing Opticians, Contact Lens Opticians
Document type:
Claim form
Issuing organization:
NHS Ophthalmic Services Wales
Deadline for submission:
14 March 2025
Training requirements:
CPD completion, WGOS 3 Low Vision mandatory training, professional certificates in Glaucoma or Medical Retina (where applicable)
Eligibility period:
1 January 2023 to 31 December 2023
Professional registration:
Must be maintained for the relevant year
Claim categories:
Contractor, employed, locum, additional certificate holders
Document Type:
Template contract
Subject:
Provision of optical services by self-employed practitioners
Parties:
Engager (Business/NHS Contractor) and Practitioner (Optometrist/OMP/Contact Lens Optician/Dispensing Optician)
Professional Registration:
GOC or GMC registration required
Scope:
Optical and related clinical services as set out in Schedule 1
Legal Context:
Employment status, tax liability, IR35 considerations
Regulatory Framework:
General Optical Council Codes of Conduct and statutory requirements
Applicable Status:
Self-employed practitioners only
Start Date:
Date of signature of the contract
Governing Considerations:
Employment law and HMRC tax guidance
Issuing Body:
Association of Optometrists (AOP)
Advisory Notes:
Disclaimer and insurance considerations included
Contractual Features:
Right of substitution, professional autonomy, mutuality of obligation, financial risk, control and integration factors
Year:
2026
Region:
Wales
Subject:
Ophthalmic Services Administration
Document Type:
Guidance / Instruction Form
Organization:
NHS Wales Shared Services Partnership
Author:
NHS Wales
Intended Audience:
Optometrists, Ophthalmic Medical Practitioners, Corporate Bodies
Effective Period:
Ongoing until updated
Approval Date:
Not specified
Amendment Date:
Not specified
Sections Included:
Section A – Opening/Relocating Premises, Section B – Change from Supplementary to Ophthalmic List, Section C – Selling or Closing Premises
Requirements:
Notification to Health Board, Completion of Supplementary Forms, References for Clinical Posts
Legal Basis:
NHS (General Ophthalmic Services) Regulations
Includes:
Instructions for new premises, status changes, temporary and permanent closures, and corporate applications
Step-by-step process:
Detailed instructions for Sections A, B, and C completion
Administrative Obligations:
Bank Mandate, Nominated Authorised Signatory Form
Official References:
Apply for Inclusion in the Ophthalmic List (Corporate Opticians) website
Year:
2021
Organization:
International Council of Accreditation (ICA)
Address:
2025 Woodlane Drive, Saint Paul, MN 55125, USA
Contact:
651-731-7243
Associated Bodies:
International Joint Commission on Allied Health Personnel in Ophthalmology (IJCAHPO), Association of Technical Personnel in Ophthalmology (ATPO), Canadian Society of Ophthalmic Medical Personnel (CSOMP), Consortium of Ophthalmic Training Programs (COTP)
Document Type:
Accreditation guidance and assessment instructions
Target Audience:
Program administrators and coordinators in ophthalmic allied health
Accreditation Cycle:
Standards reviewed every five years
Submission Format:
Electronic, using PAR templates
Required Content:
Program compliance evidence, self-assessment, final assessment tables
Fee Requirement:
Submission of appropriate fee mandatory
Year:
2019
Region / City:
England
Topic:
Heart Failure, Treatment, Cardiovascular Disease
Document Type:
Guidance
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
National Institute for Health and Care Excellence
Target Audience:
General practitioners, healthcare providers
Period of validity:
Ongoing
Approval Date:
August 2019
Date of Changes:
N/A
Year:
2018
Region / city:
London
Theme:
Dementia care, pharmacology
Document type:
Clinical guideline
Organization / institution:
London Dementia Clinical Network (NHS England and Improvement London Region)
Author:
Delia Bishara (Consultant Pharmacist, South London and Maudsley NHS Foundation Trust)
Target audience:
Healthcare professionals involved in dementia care
Effective period:
2018–present
Approval date:
Not specified
Date of amendments:
Not specified
Journal:
World Journal of Gastroenterology
Manuscript NO:
90838
Manuscript Type:
Letter to the Editor
Authors:
Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo, Stella De Nicola
Affiliations:
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy; Department of Emergency, Humanitas Research Hospital, Milan, Italy
Corresponding Author:
Francesca Colapietro, MD, Department of Biomedical Sciences, Humanitas University, Milan, Italy, [email protected]
Received:
December 15, 2023
Revised:
January 11, 2024
Accepted:
February 18, 2024
Keywords:
Chronic hepatitis B, Reactivation, Nucleoside analogue, Tyrosine kinase inhibitors, Onco-hematology
Study Type:
Case report and literature review
Patient Details:
67-year-old Caucasian male with chronic lymphocytic leukemia, HBsAg-/anti-HBc+
Treatment:
Tyrosine kinase inhibitors, specifically acalabrutinib
Clinical Outcome:
HBV reactivation with liver failure, treated with nucleos(t)ide analogues
Year:
2026
Region / City:
N/A
Topic:
Cancer research, Immunotherapy
Document Type:
Research article
Organization / Institution:
N/A
Author:
Walid S. Kamoun, Anne-Sophie Dugast, James J. Suchy, Stephanie Grabow, Ross B. Fulton, James F. Sampson, Lia Luus, Michael Santiago, Alexander Koshkaryev, Gang Sun, Vasileios Askoxylakis, Eric Tam, Zhaohua Richard Huang, Daryl C. Drummond, Andrew J. Sawyer
Target Audience:
Researchers, Oncology professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
N/A